Shares of Sanofi (NYSE:SNY) trailed the broader market last year as the company suffered an FDA rejection of its multiple sclerosis drug Lemtrada, and saw revenue fall due to patent expirations. However, CEO Chris Viehbacher recently stated in a recent CNBC interview that the company's pipeline is one of the top five in the big pharma industry.
Is he right, or overly optimistic?
Motley Fool analyst Max Macaluso examines this statement and Sanofi's overall business in the following video. He focuses on the key factors that could see the company return to growth this year, and Sanofi's unique strategy to avoid another patent cliff.
Max Macaluso, Ph.D. has no position in any stocks mentioned. The Motley Fool recommends Alnylam Pharmaceuticals. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.